Christoph Meisner

Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1

F. Jänicke, A. Prechtl, Christoph Thomssen et al. · JNCI Journal of the National Cancer Institute · 2001 · 437 citations · Full text

A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity

Jonas S. Heitmann, Tatjana Bilich, Claudia Tandler et al. · Nature · 2021 · 268 citations · Full text

Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial

Margarete Teresa Walach, Christoph Meisner, Melanie Fritz et al. · Brain · 2013 · 210 citations · Full text

A double-blind randomized placebo-controlled phase III study of a <i>Pseudomonas aeruginosa</i> flagella vaccine in cystic fibrosis patients

Gerd Döring, Christoph Meisner, Martin Stern · Proceedings of the National Academy of Sciences · 2007 · 187 citations · Full text

Vaccination, Medical Microbiology, Antibiotics +13

Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients

Nadia Harbeck, Manfred Schmitt, Christoph Meisner et al. · European Journal of Cancer · 2013 · 163 citations

Ten-year Analysis, Breast Oncology, Medicine +9